• September 3 (THU)
  • September 4 (FRI)

Sep. 3 (Thu)

ASCO/KSMO Joint Symposium

Accelerating precision medicine in real-world and utilizing real-world evidence
Date & Time Sep. 3 (Thu), 09:00-10:30 Venue Room A
Chair
  • Richard L. SCHILSKY (ASCO Executive Vice President and Chief Medical Officer, USA)
  • Tae Won KIM (Asan Medical Center, Korea)
Speaker
  1. 1.Latest findings from ASCO TAPUR study
    Richard L. SCHILSKY (ASCO Executive Vice President and Chief Medical Officer, USA)
  2. 2.Initiation of KOSMOS (Korean Precision Medicine Project)
    Jee Hyun KIM (Seoul National University Bundang Hospital, Korea)
  3. Q&A
  4. 3.CancerLINQ, ASCO's real-world data platform: Challenges and perspectives
    Cory D. WIEGERT (ASCO EVP & Chief Executive Officer, USA)
  5. 4.Research application of CancerLINQ
    Robert S. MILLER (ASCO CancerLinQ, USA)
  6. 5.Exploration of real-world Korean oncology data
    Dae Young ZANG (Hallym University Medical Center, Korea))
  7. Q&A

Scientific Symposium 1

Cutting edge of immuno-oncology
Date & Time Sep. 3 (Thu), 09:00-10:30 Venue Room B
Chair Keunchil PARK (Samsung Medical Center, Korea)
Speaker
  1. 1.Neoadjuvant checkpoint blockade for cancer immunotherapy
    Dae Ho LEE (Asan Medical Center, Korea)
  2. 2.Novel biomarkers for immuno-oncology
    Han Chong TOH (National Cancer Centre Singapore, Singapore)
  3. 3.Preclinical platform and translational strategies for cancer immunotherapy
    Shigehisa KITANO (The Cancer Institute Hospital of JFCR, Japan)

Satellite Symposium 1
Servier  boryung

Future insight for the management of pancreatic and biliary tract cancers
Date & Time Sep. 3 (Thu), 09:00-10:30
Chair Joon Oh PARK (Samsung Medical Center, Korea)
Speaker
  1. 1.Optimal continuum of care for metastatic pancreatic adenocarcinoma
    Ii Hwan KIM (Inje University Haeundae Paik Hospital, Korea)
  2. 2.Individualizing gemcitabine-based regimens in cholangiocarcinoma
    Hong Jae CHON (CHA Bundang Medical Center, Korea)
  3. 3.Liposomal irinotecan in metastatic pancreatic cancer: Asian and Korean experiences
    Changhoon YOO (Asan medical center, Korea)

Plenary Lecture 1

Date & Time Sep. 3 (Thu), 10:50-11:30 Venue Room A
Chair Young Suk Park (Samsung Medical Center, Korea)
Speaker Implementing a comprehensive translational oncology platform in precision medicine: challenges, opportunities, and new directions
Gordon B. MILLS (Knight Cancer Institute, USA)

Satellite Symposium 2
MSD

The current and future challenges: Good luck does not always repeat
Date & Time Sep. 3 (Thu), 11:30-12:10
Chair Byoung Chul CHO (Severance Hospital, Korea)
Speaker
  1. 1.Turning hope into reality: We dream for a better tomorrow with Pembrolizumab (1L NSCLC)
    Gyeong-Won LEE (Gyeongsang National University Hospital, Korea)
  2. 2.Everything comes to those who challenge: What is the best regimen for 1L R/M HNSCC patients?
    BhumSuk KEAM (Seoul National University Hospital, Korea)

Satellite Symposium 3
Roche

The beginning of immunotherapy journey in breast cancer
Date & Time Sep. 3 (Thu), 11:30-12:10
Chair Yeon Hee PARK (Samsung Medical Center, Korea)
Speaker
  1. 1.IMpassion 130: The first immune checkpoint inhibitor for 1L mTNBC patient
    Seock-Ah Im (Seoul National University Hospital, Korea)
  2. 2.Overview of current biomarkers in metastatic TNBC
    Gyungyub GONG (Asan Medical Center, Korea)

Satellite Symposium 4
Eisai

Lenvatinib treatment in first line uHCC and subsequent treatments
Date & Time Sep. 3 (Thu), 11:30-12:10
Chair Jee Hyun KIM (Seoul National University Bundang Hospital, Korea)
Speaker
  1. 1.Overseas experience on subsequent treatment after 1st Line Lenvima in uHCC (TBC)
    Stephen L. CHAN (The Chinese University of Hong Kong, Hong Kong)
  2. 2.Korean real-world experience of 1st-line Lenvima in advanced HCC
    Changhoon YOO (Asan Medical Center, Korea)

Luncheon Symposium 1
MSD

Date & Time Sep. 3 (Thu), 12:10-12:50 Venue Room A
Chair Keun Seok LEE (National Cancer Center, Korea)
Speaker MSI- H (High microsatellite instability) : Predictive biomarkers in the era of precision medicine
Seung Tae KIM (Samsung Medical Center, Korea)

Luncheon Symposium 2
Roche

Date & Time Sep. 3 (Thu), 12:10-12:50 Venue Room B
Speaker Treatment paradigm shift in HCC: the combination revolution in IMbrave150
Baek-Yeol RYOO (Asan Medical Center, Korea)

Oncology Multi-Disciplinary Symposium Korean

면역항암제의 보험시대에 임상에서 확인되는 현실적인 이슈들
Date & Time Sep. 3 (Thu), 13:20-14:20 Venue Room A
Chair
  • Se-Hoon LEE (Samsung Medical Center, Korea)
  • In Ah KIM (Seoul National University Bundang Hospital, Korea)
Speaker
  1. 1.Neoadjuvant and adjuvant immunotherapy trials in gastric cancer treatment
    Dong Seok HAN (Seoul National University Boramae Medical Center, Korea)
  2. 2.RECISTing for immunotherapy
    Ho Yun LEE (Samsung Medical Center, Korea)
  3. 3.Anti-cancer immune therapy & medical care benefit: Practical issue and unmet need
    Il Hwan KIM (Inje University Haeundae Paik Hospital, Korea)
  4. 4.Optimal use of Immunoradiotherpy: Practical issue in radiation oncology
    Si Yeol SONG (Asan Medical Center, Korea)
  5. 5.Biomarker testing for cancer immunotherapy
    Hyo Sup SHIM (Severance Hospital, Korea)
  6. Panel Discussion

Scientific Symposium 2

GU cancers
Date & Time Sep. 3 (Thu), 13:20-14:20 Venue Room B
Chair Sun Young RHA (Yonsei Cancer Center, Korea)
Speaker
  1. 1.The front-line therapy in metastatic renal cell ca
    Hyo Jin LEE (Chungnam National University Hospital, Korea)
  2. 2.Novel biomarkers and targeted therapies in urothelial carcinoma
    Seok Jae HUH (Dong-A University Hospital, Korea)
  3. 3.Clinical implementation of NGS in prostate cancer
    Jae Young JOUNG (National Cancer Center, Korea)

Scientific Symposium 3

The evolving landscape of systemic treatment of NSCLC
Date & Time Sep. 3 (Thu), 14:40-16:00 Venue Room A
Chair
  • Myung-Ju AHN (Samsung Medical Center, Korea)
  • Speaker
    1. 1.Overcoming resistance to EGFR inhibitor
      Helena A. Yu (Memorial Sloan Kettering Cancer Center, USA)
    2. 2.Overcoming resistance to ALK inhibitor
      Dong-Wan KIM (Seoul National University Hospital, Korea)
    3. 3.Biomarkers to immunotherapy
      Hye-Ryun KIM (Yeonsei Cancer Center, Korea)
    4. 4.Emerging strategies for immunotherapy combination
      Solange PETERS (Lausanne University Hospital, Switzerland)

    KOSRO/KSMO Joint Symposium

    Role of local radiotherapy in the metastatic setting
    Date & Time Sep. 3 (Thu), 14:40-16:00 Venue Room B
    Chair
    • Joo-Young Kim (National Cancer Center, Korea)
    Speaker
    1. 1.Nasophx cancer
      Hai-Qiang MAI (Sun Yat-sen University Cancer Center, China)
    2. 2.Prostate cancer
      Won PARK (Samsung Medical Center, Korea)
    3. 3.Lung cancer
      Su Ssan KIM (Asan Medical Center, Korea)

    Satellite Symposium 5
    Amgen

    Importance of bone health management in palliative setting
    Date & Time Sep. 3 (Thu), 14:40-15:20
    Chair Kyung Hee LEE (Yeungnam University Hospital, Korea)
    Speaker
    1. 1.Integrated bone health management in prostate cancer
      In-Ho KIM (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)
    2. 2.AI induced bone metastasis in Breast cancer
      Ji-Yeon KIM (Samsung Medical Center, Korea)

    Satellite Symposium 6
    menarini

    Date & Time Sep. 3 (Thu), 15:20-16:00
    Chair Junghun KANG (Gyeongsang National University Hospital, Korea)
    Speaker
    1. 1.Patient-centred treatment strategies for breakthrough cancer pain
    2. 2.Real world experience sharing from other country

    Scientific Symposium 4

    Functional genomics
    Date & Time Sep. 3 (Thu), 16:20-17:40 Venue Room A
    Chair Murim CHOI (Seoul National University, Korea)
    Speaker
    1. 1.RNA editing enzyme ADAR1 as an immuno-oncology target
      Jin Billy LI (Stanford University, USA)
    2. 2.A CRISPR-based screen for the functional assessment of BRCA1 variants
      Yongsub KIM (Asan Medical Center, Korea)
    3. 3.Genetic profiling of acanthotic seborrheic keratosis
      Murim CHOI (Seoul National University, Korea)
    4. 4.Werner helicase is a synthetic-lethal target in mismatch repair deficient tumours
      Mathew J. GARNETT (Wellcome Sanger Institute, UK)

    Scientific Symposium 5

    Progress in precision medicine
    Date & Time Sep. 3 (Thu), 16:20-17:40 Venue Room B
    Chair Ji-Youn HAN (National Cancer Center, Korea)
    Speaker
    1. 1.New uses of existing targeted drugs: DRUP Trial by the Netherlands Cancer Institute
      Emile VOEST (Netherlands Cancer Institute, Netherlands)
    2. 2.MASTER KEY project: A biomarker-driven platform trial for rare cancers
      Yasuhiro FUJIWARA (Pharmaceuticals and Medical Devices Agency, Japan)
    3. 3.Comprehensive genomic profiling in translational cancer research
      Tae Min KIM (Seoul National University Hospital, Korea)
    4. 4.Incorporating imaging biomarkers in clinical trial design
      Kyung Won KIM (Asan Medical Center, Korea)

    Satellite Symposium 7
    Sanofi

    What is being considered for continuum of care in metastatic colorectal cancer?
    Date & Time Sep. 3 (Thu), 16:20-17:00
    Chair Joong-Bae AHN (Yonsei University, Korea)
    Speaker
    1. 1.Biomarker driven 2nd line treatment for patients with mCRC: Insights in Biomarker
      Dirk ARNOLD (University of Hamburg, Germany)
    2. 2.Choosing anti-VEGF agents in 2nd line treatment for mCRC: Korean experience
      Seunghoon Beom (Yonsei University, Korea)

    Plenary Lecture 2

    Date & Time Sep. 3 (Thu), 17:40-18:40 Venue Room A
    Chair Tae Won KIM (Asan Medical Center, Korea)
    Speaker Functional genomics approaches to identify targetable dependencies in cancer cells
    Mathew J. GARNETT (Wellcome Sanger Institute, UK)

    Sep. 4 (Thu)

    Scientific Symposium 6

    CRC
    Date & Time Sep. 4 (Fri), 08:00-09:00 Venue Room A
    Chair Joong-Bae AHN (Yonsei Cancer Center, Korea)
    Speaker
    1. 1.Developing new target agents in colorectal cancer (RAS/RAF)
      Scott KOPETZ (The University of Texas MD Anderson Cancer Center, USA)
    2. 2.Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
      Yongjun CHA (National Cancer Center, Korea)
    3. 3.Neoadjuvant chemotherapy in operable colon cancer
      Soohyeon LEE (Korea University Anam Hospital, Korea)

    Scientific Symposium 7

    Breast cancer
    Date & Time Sep. 4 (Fri), 08:00-09:00 Venue Room B
    Chair KyungHae JUNG (Asan Medical Center, Korea)
    Speaker
    1. 1.The role of immunotherapies in breast cancer management
      Lajos PUSZTAI (Yale Cancer Center, USA)
    2. 2.Interplay between immunotherapy and CDK4/6 inhibitors in breast cancer
      Gregory VIDAL (West Cancer Center, USA)

    Satellite Symposium 8
    MeRcK

    New indication(s) of PD-L1 inhibitor, Bavencio
    Date & Time Sep. 4 (Fri), 08:00-08:40
    Speaker

    ASCO Breakthrough Session

    KSMO-ASCO breakthrough insights: Bench to bedside research in oncology
    Date & Time Sep. 4 (Fri), 09:00-10:30 Venue Room A
    Chair
    • Howard A. BURRIS (Sarah Cannon Research Institute, USA)
    • Tae-You KIM (Seoul National University Hospital, Korea)
    Speaker
    1. 1.Learning about carcinogenesis and drug sensitivity from organoids
      Shiladitya SENGUPTA (Harvard Medical School, USA)
    2. 2.Clinical application of organoids for cancer diagnosis and treatment
      Young Seok JU (KAIST, Korea)
    3. Panel Discussion
    4. 3.Microbiota, immune-tonus, and cancer: Biology
      Thomas F. GAJEWSKI (The University of Chicago, USA)
    5. 4.Microbiota, immune-tonus, and cancer: Clinical applications
      Siew C NG (The Chinese University of Hong Kong, Hong Kong)
    6. Panel Discussion

    Special Symposium 1

    Opening a new chapter in clinical research of Korea BioPharm
    Date & Time Sep. 4 (Fri), 09:00-10:30 Venue Room B
    Chair
    • Yung-Jue BANG (Bang&Oak Consulting, Korea)
    • Min-Hee RYU (Asan Medical Center, Korea)
    Speaker
    1. 1.GX-I7 (Interleukin-7-hyFc) plus immune checkpoint inhibitor in TNBC, GBM, Melanoma
      Jung Won WOO (Genexine, Inc., Korea)
    2. 2.Belvarafenib, a selective and orally bioavailable type II RAF dimer inhibitor
      SeungJae BAEK (Hanmi Pharmaceuticals, Korea)
    3. 3.ALT-P7 (HM2/MMAE antibody-drug conjugate) in HER2+ metastatic breast
      Sunbae LEE (Alteogen, Inc., Korea)
    4. 4.Olinvacimab (aVEGF2 mAb) plus immune checkpoint inhibitor in TNBC, GBM
      Jin-San YOO (PharmAbcine, Korea)

    Satellite Symposium 9
    Pfizer

    New perspectives for treatment naïve patients with EGFR+ non small cell lung cancer
    Date & Time Sep. 4 (Fri), 09:00-09:40
    Speaker
    1. 1.Treatment for EGFR+ NSCLC: Where are we now?
      Hye-Ryun KIM (Yeonsei Cancer Center, Korea)
    2. 2.Optimal treatment sequence in EGFR+ non-small cell lung cancer
      Mok Shu Kam TONY (The Chinese University of Hong Kong, Hong Kong)

    Plenary Lecture 3

    Date & Time Sep. 4 (Fri), 10:50-11:30 Venue Room A
    Chair Hyun Choel CHUNG (Severance Hospital, Korea)
    Speaker Therapeutic targeting of the TAM receptor family in cancer
    Amato Giaccia (Oxford Institute of Radiation Oncology, UK)

    Satellite Symposium 10
    Lilly

    Continuing Advances in metastatic Breast Cancer: How to make optimal treatment decision for metastatic breast cancer patients
    Date & Time Sep. 4 (Fri), 10:50-11:30
    Speaker
    1. 1.Role of prognostic factor in treatment choice for HR+, HER2- metastatic breast cancer patients
      Gregory Vidal (Western Cancer Center, USA)
    2. 2.Continuing advances in metastatic breast cancer: Clinical overview of Abemaciclib
      Hee Kyung AHN (Gachon University Gil Medical Center, Korea)

    Satellite Symposium 11
    Takeda

    Treatment options for patients with ALK+ NSCLC: How is the paradigm changing?
    Date & Time Sep. 4 (Fri), 10:50-11:30
    Chair Myung-Ju AHN (Samsung Medical Center, Korea)
    Speaker
    1. 1.Long-term survival for patients with ALK+ NSCLC: An achievable aim?
      Mok Shu Kam TONY (The Chinese University of Hong Kong, Hong Kong)
    2. 2.New Standards of Care in post crizotinib ALK+NSCLC: Roles of brigatinib in optimal sequential treatments
      Min Hee HONG (Severance Hospital, Korea)

    Noe Kyeong Kim Memorial Award & Lecture

    Date & Time Sep. 4 (Fri), 11:30-12:10 Venue Room A
    Chair Hoon Kyo KIM (National OncoVenture, Korea)
    Speaker Clinical investigation for the management of advanced gastrointestinal stromal tumor (GIST)
    Yoon-Koo KANG (Asan Medical Center, Korea)

    Satellite Symposium 12
    ONO/BMS

    Ever forward with cancer immunotherapy: the progress so far and new frontiers
    Date & Time Sep. 4 (Fri), 11:30-12:10
    Chair Byoung Chul CHO (Severance Hospital, Korea)
    Speaker
    1. 1.Optimal Therapeutic Strategies for Esophageal cancer
      Jong Mu SUN (Samsung Medical Center, Korea)
    2. 2.Big Journey of Immunotherapy for NSCLC in Korea
      Sun Min LIM (Yonsei Cancer Center, Korea)

    Satellite Symposium 13
    BAYER

    From concept to practice - new era of precision medicine
    Date & Time Sep. 4 (Fri), 11:30-12:10
    Speaker Larotrecitinb, “The REAL DRUG” for TRK fusion cancer patients
    Do-Youn OH (Seoul National University Hospital, Korea)

    Luncheon Symposium 3
    Novartis

    Date & Time Sep. 4 (Fri), 12:10-12:50 Venue Room A
    Chair Sung-Bae KIM (Asan Medical Center, Korea)
    Speaker Treatment landscape for HR+/HER2- aBC: Focusing on CDK4/6 pathway
    Seock-Ah IM (Seoul National University Hospital, Korea)

    Luncheon Symposium 4
    AstraZeneca

    Date & Time Sep. 4 (Fri), 12:10-12:50 Venue Room B
    Speaker Cutting-edge front-line treatment for advanced non-small cell lung cancer
    Stephen CLARKE (Royal North Shore Hospital, Australia)

    KCSG/KSMO Joint Symposium

    Expanding the field of clinical trials to fulfill unmet clinical needs
    Date & Time Sep. 4 (Fri), 13:20-14:20 Venue Room A
    Chair
    • Joung Soon JANG (Chung-Ang University Hospital, Korea)
    • Jin-Hyoung KANG (The Catholic University of Korea Seoul St. Mary’s Hospital, Korea)
    Speaker
    1. 1.Collaboration with multinational study groups
      Kun WANG (Guangdong Provincial People's Hospital, China)
    2. 2.Conducting clinical trials with multi-disciplinary collaboration
      Joohyuk SOHN (Yonsei Cancer Center, Korea)
    3. 3.Early phase clinical trials: Win-win strategies for investigator and company
      Sang-Yoon LEE (Interpark Bio-Convergence Center, Korea)

    KSSO/KSMO Joint Symposium

    Evolving role of surgery in a multidisciplinary approach
    Date & Time Sep. 4 (Fri), 13:20-14:20 Venue Room B
    Chair
    • Young Joo MIN (Ulsan University Hospital, Korea)
    Speaker
    1. 1.Conversion surgery in metastatic gastric cancer
      Keun-Wook LEE (Seoul National University Bundang Hospital, Korea)
    2. 2.Conversion surgery in metastatic gastric cancer
      Han-Kwang YANG (Seoul National University Hospital, Korea)
    3. Discussion
    4. 1.Watch-and-wait after clinical complete response in rectal cancer
      Myung Ah LEE (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)
    5. 2.Watch-and-wait after clinical complete response in rectal cancer
      Woo Yong LEE (Samsung Medical Center, Korea)
    6. Discussion

    Multidisciplinary Oncology Team Education Session 1 Korean

    Understanding new paradigms of oncology clinical research & practice
    Date & Time Sep. 4 (Fri), 13:20-14:20 Venue Room C
    Chair Hyo Jin LEE (Chungnam National University Hospital, Korea)
    Speaker
    1. 1.Toward precision targeted therapy
      Jihoon KANG (Kangbuk Samsung Hospital, Korea)
    2. 2.Boosting cancer immunotherapy
      In-Ho KIM (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)
    3. 3.Evolving role of biomarker in clincial trial
      Yoon Ji CHOI (Korea University Anam Hospital, Korea)

    FACO Session 1

    Update of FACO clinical trials
    Date & Time Sep. 4 (Fri), 13:20-14:20 Venue Room D
    Chair
    • Jin LI (Tongji University, China)
    • Yeon Hee PARK (Samsung Medical Center, Korea)
    Speaker
    1. 1.Oligo-BC 1
      Shigeru IMOTO (Kyorin University, Japan)
    2. 2.PC-CURE-1
      Junji FURUSE (Kyorin University, Japan)

    JSMO/KSMO Joint Symposium

    Clinical genomics: Challenges and opportunities
    Date & Time Sep. 4 (Fri), 14:40-16:00 Venue Room A
    Chair
    • Young-Hyuck IM (Samsung Medical Center, Korea)
    • Chikashi ISHIOKA (Tohoku University School of Medicine, Japan)
    Speaker
    1. 1.Clinical relevance of genomics in cancer medicine in Japan
      Koichi GOTO (National Cancer Center Hospital East, Japan)
    2. 2.Implementation of genomics in medical practice in Korea
      Se-Hoon LEE (Samsung Medical Center, Korea)
    3. 3.Cancer immunogenomics
      Yosuke TOGASHI (Chiba Cancer Center, Japan)
    4. 4.Application of single cell genomics in precision medicine
      Woong-Yang PARK (Samsung Genome Institute, Korea)

    KSP/KSMO Joint Symposium

    Updated cancer diagnosis platform: Present and future
    Date & Time Sep. 4 (Fri), 14:40-16:00 Venue Room B
    Chair
    • Jae Hong SEO (Korea University Guro Hospital, Korea)
    • Geon Kook LEE (National Cancer Center, Korea)
    Speaker
    1. 1.Cancer diagnosis through digital platform: Present and near future
      Jin ROH (Ajou University Hospital, Korea)
    2. 2.Virtual slide consultation of pathologic frozen examination
      Kee-Taek JANG (Samsung Medical Center, Korea)
    3. 3.Intraoperative handheld laser microscopy in cancer diagnostics
      Kate E. YU (VPIX Medical, Korea)
    4. 4.New upcoming cancer diagnosis tools
      Chaithanya CHELAKKOT (GenoBio, Korea)

    Multidisciplinary Oncology Team Education Session 2 Korean

    Precision medicine in real-world
    Date & Time Sep. 4 (Fri), 14:40-16:00 Venue Room C
    Chair Seungtaek LIM (Wonju Severance Christian Hospital, Korea)
    Speaker
    1. 1.Precision medicine in clinical practice
      Min Hee HONG (Severance Hospital, Korea)
    2. 2.Advancing molecular tumor boards
      Yun-Gyoo LEE (Kangbuk Samsung Hospital, Korea)
    3. 3.Oncology pharmacist’s role in precision medicine
      JungHyun KIM (Samsung Medical Center, Korea)

    FACO Session 2

    Advance of immuno-oncologic strategies for Asian cancer patients
    Date & Time Sep. 4 (Fri), 14:40-16:00 Venue Room D
    Chair
    • Masahiko NISHIYAMA (Gunma University, Japan)
    • Rui-hua XU (Sun Yat-sen University Cancer Center, China)
    Speaker
    1. 1.Current status of IO incorporation for NSCLC in Korea
      Hee Kyung AHN (Gachon University Gil Medical Center, Korea)
    2. 2.Adaptation of IO agents to for GI precision medicine in China
      Xiaotian ZHANG (Peking University Cancer Hospital, China)
    3. 3.Immunotherapy, CDK4/6 Inhibitors, and new agents for breast cancer in Japan
      Toshimi TAKANO (The Cancer Institute Hospital of JFCR, Japan)

    Scientific Symposium 8

    GC/HBP cancers
    Date & Time Sep. 4 (Fri), 16:20-17:40 Venue Room A
    Chair Jae Yong CHO (Gangnam Severance Hospital, Korea)
    Speaker
    1. 1.Prospects for immunotherapy and targeted therapy in gastric cancer
      Do-Youn OH (Seoul National University Hospital, Korea)
    2. 2.Promising new treatments in biliary tract cancer
      Joon Oh PARK (Samsung Medical Center, Korea)
    3. 3.Further treatment strategies beyond PARPi therapy in pancreatic cancer
      Li-Tzong CHEN (National Institute of Cancer Research, Taiwan)
    4. 2.Challenges in systemic therapy in hepatocellular carcinoma
      Baek-Yeol RYOO (Asan Medical Center, Korea)

    Scientific Symposium 9

    Discovery of novel therapeutic targets
    Date & Time Sep. 4 (Fri), 16:20-17:40 Venue Room B
    Chair Jeeyun LEE (Samsung Medical Center, Korea)
    Speaker
    1. 1.KRAS: An undruggable drug target that drives antitumor activity
      Gerald S. FALCHOOK (Sarah Cannon Research Institute at HealthONE, USA)
    2. 2.A new mechanism for NK cell exclusion from solid tumors
      Amato Giaccia (Oxford Institute of Radiation Oncology, UK)
    3. 3.YAP-TEAD binding: Therapeutic approach for targeting HIPPO signaling pathway
      Hwan Jung LIM (Korea Research Institute of Chemical Technology, Korea)

    Multidisciplinary Oncology Team Education Session 3 Korean

    Multidisciplinary approaches in immuno-oncology incorporated into clinical practice
    Date & Time Sep. 4 (Fri), 16:20-17:40 Venue Room C
    Chair Byeong Seok SOHN (Inje University Sanggye Paik Hospital, Korea)
    Speaker
    1. 1.Immuno-oncology in clinical practice
      Soo Jung LEE (Kyungpook National University Chilgok Hospital, Korea)
    2. 2.Biomarkers for immuno-oncology
      Chi Hoon MAENG (Kyung Hee University Hospital, Korea)
    3. 3.Monitoring and management of immune-related adverse events
      Shinkyo YOON (Asan Medical Center, Korea)

    Satellite Symposium 14
    Daewoong  Samsung Bioepis

    Date & Time Sep. 4 (Fri), 16:20-17:00
    Chair
  • Sung-Bae KIM (Asan Medical Center, Korea)
  • Speaker Building confidence in Biosimilars: From data to patient
    Seongwon HAN (Samsung Bioepis , Korea)